While J&J expects tariffs will cost it $400 million this year, the company maintained its earnings estimate and upped its sales guidance for 2025.

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether other drugs like it would similarly struggle in testing.

The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S.

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

Using integrated lab, claims, and EMR data, the manufacturer can pull in test results and deploy NLP on the unstructured EMR ...

The Atlas-backed company plans to liquidate its assets, including an experimental drug for chronic spontaneous urticaria it ...

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

The initiative, which will start with monoclonal antibodies, is the first big regulatory shift from the FDA since Martin ...

La., had invited Kennedy to testify April 10 on the sweeping layoffs of federal health workers Kennedy ordered last month. A ...